Seminars in Diagnostic Pathology
Volume 23, Issue 1 , Pages 35-43 , February 2006

The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma

  • Ben Davidson, MD, PhD

      Affiliations

    • Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway
    • Corresponding Author InformationAddress reprint requests and correspondence: Ben Davidson, MD, PhD, Department of Pathology, The Norwegian Radium Hospital-National Hospital, Montebello N-0310 Oslo, Norway.
    • ,
  • Björn Risberg, MD, PhD

      Affiliations

    • Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway
    • ,
  • Aasmund Berner, MD, PhD

      Affiliations

    • Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway
    • ,
  • Carlos W.M. Bedrossian, MD, PhD (Hon), FIAC

      Affiliations

    • Department of Pathology, Norwegian American Hospital, Chicago, Illinois
    • ,
  • Reuven Reich, PhD

      Affiliations

    • R.R. is affiliated with the David R. Bloom Center for Pharmacy at the Hebrew University.
    • Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

References 

  1. Spirtas R , Connelly RR , Tucker MA . Survival patterns for malignant mesothelioma: the SEER experience . Int J Cancer . 1988;41:525–530
  2. Sugarbaker PH , Welch LS , Mohamed F , Glehen O . A review of peritoneal mesothelioma at the Washington Cancer Institute . Surg Oncol Clin North Am . 2003;12:605–621
  3. Antman KH , Corson JM , Li FP , et al.   Malignant mesothelioma following radiation exposure . J Clin Oncol . 1983;1:695–700
  4. Riddell RH , Goodman MJ , Moossa AR . Peritoneal malignant mesothelioma in a patient with recurrent peritonitis . Cancer . 1981;48:134–139
  5. Maurer R , Egloff B . Malignant peritoneal mesothelioma after cholangiography with thorotrast . Cancer . 1975;36:1381–1385
  6. Baker PM , Clement PB , Young RH . Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis . Am J Clin Pathol . 2005;123:724–737
  7. Park BJ , Alexander HR , Libutti SK , et al.   Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP) . Ann Surg Oncol . 1999;6:582–590
  8. Loggie BW , Fleming RA , McQuellon RP , et al.   Prospective trial for the treatment of malignant peritoneal mesothelioma . Am Surg . 2001;67:999–1003
  9. Kerrigan SA , Tumnir RT , Clement PB , et al.   Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients . Cancer . 2002;94:378–385
  10. Feldman AL , Libutti SK , Pingpank JF , et al.   Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy . J Clin Oncol . 2003;21:4560–4567
  11. Deraco M , Casali P , Inglese MG , et al.   Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion . J Surg Oncol . 2003;83:147–153
  12. Janne PA , Wozniak AJ , Belani CP , et al.   Open-label study of pemetrexed alone or in combination with Cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program . Clin Lung Cancer . 2005;7:40–46
  13. Yan TD , Haveric N , Carmignani CP , et al.   Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy . Cancer . 2005;103:839–849
  14. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  15. Davidson B , Risberg B , Reich R , et al.   Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis . Clin Lab Med . 2003;23:729–754
  16. See HT , Kavanagh JJ , Hu W , et al.   Targeted therapy for epithelial ovarian cancer: current status and future prospects . Int J Gynecol Cancer . 2003;13:701–734
  17. Bedrossian CWM . Malignant Effusions: A Multimodal Approach to Cytologic Diagnosis . New York, NY: Igaku-Shoin; 1994;
  18. Bedrossian CWM . Diagnostic problems in serous effusions . Diagn Cytopathol . 1998;19:131–137
  19. Davidson B , Nielsen S , Christensen J , et al.   The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells . Am J Surg Pathol . 2001;25:1405–1412
  20. Ordonez NG . Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas . Am J Surg Pathol . 1998;22:1203–1214
  21. Scharnhorst V , van der Eb AJ , Jochemsen AG . WT1 proteins: functions in growth and differentiation . Gene . 2001;273:141–161
  22. Kumar-Singh S , Segers K , Rodeck U , et al.   WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis . J Pathol . 1997;181:67–74
  23. Waldstrom M , Grove A . Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas . Arch Pathol Lab Med . 2005;129:85–88
  24. Drapkin R , Crum CP , Hecht JL . Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia . Hum Pathol . 2004;35:1014–1021
  25. Borczuk AC , Taub RN , Hesdorffer M , et al.   P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma . Clin Cancer Res . 2005;11:3303–3308
  26. Barbacid M . Neurotrophic factors and their receptors . Curr Opin Cell Biol . 1995;7:148–155
  27. Kaplan DR , Miller FD . Signal transduction by the neurotrophin receptors . Curr Opin Cell Biol . 1997;9:213–221
  28. Patapoutian A , Reichardt LF . Trk receptors: mediators of neurotrophin action . Curr Opin Neurobiol . 2001;11:272–280
  29. Barker PA , Lomen-Hoerth C , Gensch EM , et al.   Tissue-specific alternative splicing generates two isoforms of the trkA receptor . J Biol Chem . 1993;268:15150–15157
  30. Weismann C , Ultsch MH , Bass SH , et al.   Crystal structure of the nerve growth factor in complex with the ligand-binding domain of the TrkA receptor . Nature . 1999;401:184–188
  31. Greene LA , Kaplan DR . Early events in neurotrophin signalling via Trk and p75 receptors . Curr Opin Neurobiol . 1995;5:579–587
  32. Kaplan DR , Miller FD . Neutrophin signal transduction in the nervous system . Curr Opin Neurobiol . 2000;10:381–391
  33. Roux PP , Barker PA . Neurotrophin signaling through the p75 neurotrophin receptor . Prog Neurobiol . 2002;67:203–233
  34. Nakagawara A . Trk receptor tyrosine kinases: a bridge between cancer and neural development . Cancer Lett . 2001;169:107–114
  35. Shibayama E , Koizumi H . Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues . Am J Pathol . 1996;148:1807–1818
  36. McGregor LM , McCune BK , Graff JR , et al.   Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression . Proc Natl Acad Sci USA . 1999;96:4540–4545
  37. Davidson B , Lazarovici P , Ezersky A , et al.   Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients . Clin Cancer Res . 2001;7:3457–3464
  38. Davidson B , Reich R , Lazarovici P , et al.   Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma . Clin Cancer Res . 2003;9:2248–2259
  39. Davidson B , Reich R , Lazarovici P , et al.   Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma . Breast Cancer Res Treat . 2004;83:119–128
  40. Davidson B , Reich R , Lazarovici P , et al.   Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma . Lung Cancer . 2004;44:159–165
  41. Folkman J . Tumor angiogenesis . Adv Cancer Res . 1985;43:175–203
  42. Folkman J . What is the evidence that tumors are angiogenesis dependent? . J Natl Cancer Inst . 1990;82:4–6
  43. Fidler IJ , Ellis LM . The implications of angiogenesis for the biology and therapy of cancer metastasis . Cell . 1994;79:185–188
  44. Folkman J , Klagsbrun M . Angiogenic factors . Science . 1987;235:442–447
  45. Tischer E , Mitchell R , Hartman T , et al.   The human gene for vascular endothelial growth factor . J Biol Chem . 1991;226:11947–11954
  46. Keck PJ , Hauser SD , Krivi G , et al.   Vascular permeability factor: an endothelial cell mitogen related to PDGF . Science . 1989;246:1309–1312
  47. Goldfarb M . The fibroblast growth factor family . Cell Growth Diff . 1990;1:439–445
  48. Gospodarowicz D , Neufeld G , Schweigerer L . Molecular and biological characterization of fibroblast growth factor: an angiogenic growth factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells . Cell Diff . 1986;19:1–17
  49. Koch AE , Polverini PJ , Kunkel SL , et al.   Interleukin-8 as a macrophage-derived mediator of angiogenesis . Science . 1992;258:1798–1801
  50. Vlodavsky I , Friedmann Y . Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis . J Clin Invest . 2001;108:341–347
  51. Parish CR , Freeman C , Hulett MD . Heparanase: a key enzyme involved in cell invasion . Biochim Biophys Acta . 2001;1471:M99–M108
  52. Kumar-Singh S , Weyler J , Martin MJH , et al.   Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGFβ expression . J Pathol . 1999;189:72–78
  53. Strizzi L , Catalano A Vianale G , et al.   Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma . J Pathol . 2001;193:468–475
  54. Konig J , Tolnay E , Wiethege T , et al.   Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma . Respiration . 2000;67:36–40
  55. Konig JE , Tolnay E , Wiethege T , et al.   Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma . Virchows Arch . 1999;435:8–12
  56. Ohta Y , Shridhar V , Bright RK , et al.   VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours . Br J Cancer . 1999;81:54–61
  57. Catalano A , Romano M , Martinotti S , et al.   Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T cell antigen . Oncogene . 2002;21:2896–2900
  58. Davidson B , Vintman L , Zcharia E , et al.   Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma . Clin Exp Metastasis . 2004;21:469–476
  59. Klominek J , Baskin B , Hauzenberger D . Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction . Clin Exp Metastasis . 1998;16:529–539
  60. Ascoli V , Scalzo CC , Facciolo F , et al.   Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions . Acta Cytol . 1995;39:613–622
  61. Langerak AW , De Laat PA , Van Der Linden–Van Beurden CA , et al.   Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo . J Pathol . 1996;178:151–160
  62. Galffy G , Mohammed KA , Dowling PA , et al.   Interleukin 8: an autocrine growth factor for malignant mesothelioma . Cancer Res . 1999;59:367–371
  63. Strizzi L , Vianale G , Catalano A , et al.   Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis . Int J Oncol . 2001;18:1093–1098
  64. Abulafia O , Triest WE , Sherer DM . Angiogenesis in primary and metastatic epithelial ovarian carcinoma . Am J Obstet Gynecol . 1997;177:541–547
  65. Di Blasio AM , Cremonesi L , Vigano P , et al.   Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms . Am J Obstet Gynecol . 1993;169:1517–1523
  66. Davidson B , Goldberg I , Kopolovic J , et al.   Expression of angiogenesis-related genes in ovarian carcinoma (A clinicopathologic study) . Clin Exp Metastasis . 2000;18:501–507
  67. Boocock CA , Charnock-Jones DS , Sharkey AM , et al.   Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma . J Natl Cancer Inst . 1995;87:506–516
  68. Barton DPJ , Cai A , Wendt K , et al.   Angiogenic protein expression in advanced epithelial ovarian cancer . Clin Cancer Res . 1997;3:1579–1586
  69. Davidson B , Reich R , Kopolovic J , et al.   Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions . Clin Exp Metastasis . 2002;19:135–144
  70. Konstantinovsky S , Nielsen S , Vyberg M , et al.   Angiogenic molecule expression is downregulated in effusions from breast cancer patients . Breast Cancer Res Treat . 2005;94:71–80
  71. Kleinman HK , Koblinski J , Lee S , et al.   Role of basement membrane in tumor growth and metastasis . Surg Oncol Clin North Am . 2001;10:329–338
  72. Hood JD , Cheresh DA . Role of integrins in cell invasion and migration . Nat Rev . 2002;2:91–100
  73. Ruoslahti E . Integrins . J Clin Invest . 1991;87:1–5
  74. Sanders RJ , Mainiero F , Giancotti FP . The role of integrins in tumorigenesis and metastasis . Cancer Invest . 1998;16:329–344
  75. Menard S , Castronovo V , Tagliabue E , et al.   New insights into the metastasis-associated 67 kD laminin receptor . J Cell Biochem . 1997;67:155–165
  76. Menard S , Tagliabue E , Colnaghi MI . The 67 kDa laminin receptor as a prognostic factor in human cancer . Breast Cancer Res Treat . 1998;52:137–145
  77. Givant-Horwitz V , Davidson B , Reich R . Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor . Cancer Res . 2004;64:3572–3579
  78. Klominek J , Sumitran Karupan S , Hauzenberger D . Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of β1 integrins . Int J Cancer . 1997;72:1034–1044
  79. Koukoulis GK , Shen J , Monson R , et al.   Pleural mestheliomas have an integrin profile distinct from visceral carcinomas . Hum Pathol . 1997;28:84–90
  80. Givant-Horwitz V , Davidson B , van de Putte G , et al.   Expression of the 67kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma . Clin Exp Metastasis . 2003;20:599–609
  81. Davidson B , Goldberg I , Reich R , et al.   The αv and β1 integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients . Gynecol Oncol . 2003;90:248–257
  82. Sigstad E , Dong HP , Nielsen S , et al.   Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping . Diagn Cytopathol . 2005;33:321–331
  83. Reich R , Vintman L , Nielsen S , et al.   Differential expression of the 67 kilodalton laminin receptor in malignant mesothelioma and carcinomas that spread to serosal cavities . Diagn Cytopathol . 2005;33:332–337
  84. Egeblad M , Werb Z . New functions for the matrix metalloproteinases in cancer progression . Nat Rev Cancer . 2002;2:161–174
  85. Davidson B , Goldberg I , Gotlieb WH , et al.   High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma . Clin Exp Metastasis . 1999;17:799–808
  86. Davidson B , Reich R , Berner A , et al.   Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels . Eur J Cancer . 2001;37:2040–2049
  87. Davidson B , Goldberg I , Berner A , et al.   Expression of membrane-type 1,2 and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions . Am J Clin Pathol . 2001;115:517–524
  88. Liu Z , Klominek J . Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors . Thorax . 2003;58:198–203
  89. Harvey P , Clark IM , Jaurand MC , et al.   Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases . Br J Cancer . 2000;83:1147–1153
  90. Edwards JG , McLaren J , Jones JL , et al.   Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura . Br J Cancer . 2003;88:1553–1559
  91. Moretta L , Biassoni R , Bottino C , et al.   Human NK cells and their receptors . Microbes Infect . 2002;4:1539–1544
  92. Algarra I , Garcia-Lora A , Cabrera T , et al.   The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape . Cancer Immunol Immunother . 2004;53:904–910
  93. van der Ven K , Pfeiffer K , Skrablin S . HLA-G polymorphisms and molecule function- questions and more questions: a review . Placenta . 2000;21:S86–S92 (suppl A)
  94. Hofmeister V , Weiss EH . HLA-G modulates immune responses by diverse receptor interactions . Semin Cancer Biol . 2003;13:317–323
  95. Brostjan C , Bellon T , Sobanov Y , et al.   Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones . J Immunol Methods . 2002;264:109–119
  96. McMaster MT , Librach CL , Zhou Y , et al.   Human placental HLA-G expression is restricted to differentiated cytotrophoblasts . J Immunol . 1995;154:3771–3778
  97. McMaster M , Zhou Y , Shorter S , et al.   HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation . J Immunol . 1998;160:5922–5928
  98. Paul P , Rouas-Freiss N , Khalil-Daher I , et al.   HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance . Proc Natl Acad Sci USA . 1998;95:4510–4515
  99. Urosevic M , Willers J , Mueller B , et al.   HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas . Blood . 2002;99:609–617
  100. Singer G , Kurman RJ , McMaster M , et al.   HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis . Am J Surg Pathol . 2002;26:914–920
  101. Bukur J , Rebmann V , Grosse-Wilde H , et al.   Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma . Cancer Res . 2003;63:4107–4111
  102. Urosevic M , Kurrer MO , Kamarashev J , et al.   Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production . Am J Pathol . 2001;159:817–824
  103. Lefebvre S , Antoine M , Uzan S , et al.   Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer . J Pathol . 2002;196:266–274
  104. Singer G , Rebmann V , Chen YC , et al.   HLA-G is a potential tumor marker in malignant ascites . Clin Cancer Res . 2003;9:4460–4464
  105. Davidson B , Bukholt Elstrand M , McMaster MT , et al.   HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma . Gynecol Oncol . 2005;96:42–47
  106. Kleinberg L , Florenes VA , Skrede M , et al.   Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma . Virchows Arch . 2006;449:31–39
  107. Dong HP , Bunkholt Elstrand M , Holth A , et al.   NK and B cell infiltration correlates with worse outcome in metastatic ovarian carcinoma . Am J Clin Pathol . 2006;125:451–458
  108. Denhardt DT . Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling . Biochem J . 1996;318:729–747
  109. Garrington TP , Johnson GL . Organization and regulation of mitogen-activated protein kinase signaling pathways . Curr Opin Cell Biol . 1999;11:211–218
  110. Fanger GR . Regulation of the MAPK family members: role of subcellular localization and architectural organization . Histol Histopathol . 1999;14:887–894
  111. Chang L , Karin M . Mammalian MAP kinase signalling cascades . Nature . 2001;410:37–40
  112. Davis RJ . MAPKs: new JNK expands the group . Trends Biochem Sci . 1994;19:470–473
  113. Givant-Horwitz V , Davidson B , Lazarovici P , et al.   Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions . Gynecol Oncol . 2003;91:160–172
  114. Givant-Horwitz V , Davidson B , Goderstad JM , et al.   The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma . Gynecol Oncol . 2004;93:517–523
  115. Vintman L , Nielsen S , Berner A , et al.   Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells . Cancer . 2005;103:2427–2433

PII: S0740-2570(06)00086-4

doi: 10.1053/j.semdp.2006.06.003

Seminars in Diagnostic Pathology
Volume 23, Issue 1 , Pages 35-43 , February 2006

Article Tools

* Image Usage & Resolution